drugset / Trial / NCT02743260
Drug Transporter Interaction Study PHENTRA_2015_KPUK
Phase 4
Completed
24 enrolled
University of Cologne
Institute for Biomedical and Pharmaceutical Research (IBMP), Nürnberg-Heroldsberg, Germany · collabUmm Al-Qura University · collab
RandomizedCrossoverOpen-labelBasic science
Summary
The objective of the present study is to contribute to establishing in vivo phenotyping procedures for organic anionic transporter polypeptide 1B1 (OATP1B1), organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K), organic anion transporters 1 and 3 (OAT1/3), and p-glycoprotein (P-gp) transporters via a cocktail approach. To this end, marker substrates for each of the respective transporters are administered as single doses in one period each and as a cocktail in one period to 24 healthy volunteers, and phenotyping metrics are derived from plasma and urine concentrations.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-12
- Completion
- 2017-12
Publications
- Hsin CH, Stoffel MS, Gazzaz M, Schaeffeler E, Schwab M, Fuhr U, Taubert M. Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Sci Rep. 2020 Jul 27;10(1):12457. doi: 10.1038/s41598-020-69326-y.
- Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, Kinzig M, Sorgel F, Stoffel MS, Fuhr U. A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. Clin Pharmacol Ther. 2019 Dec;106(6):1398-1407. doi: 10.1002/cpt.1564. Epub 2019 Aug 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir | Unknown | 10 mg | Oral |
| Subject | Digoxin | Other / unclassified | 0.5 mg | Oral |
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Subject | Pitavastatin | Small molecule | 2 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
Indications
No indication recorded.